IMC-1121B

BIOLOGICAL4 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced Solid TumorsCancerSolid Tumor

Phase 1

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

CompletedNCT00786383

Eli Lilly and CompanyCancer

Start: 2006-02-28End: 2009-01-31Updated: 2013-08-19

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

CompletedNCT00793975

Eli Lilly and CompanyAdvanced Solid Tumors

Start: 2005-01-31End: 2009-06-30Updated: 2013-08-19

Study of IMC-1121B in Patients With Advanced Solid Tumors

CompletedNCT01005355

Eli Lilly and CompanyAdvanced Solid Tumors

Start: 2009-09-30End: 2011-02-28Updated: 2014-06-18

Phase 2

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

CompletedNCT01017731

Eli Lilly and CompanyCancer, Solid Tumor

Start: 2009-11-30End: 2014-05-31Updated: 2015-06-10

Related Papers

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.

2017-04-016 citations

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

2015-03-1859 citations